Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Healthcare: Aurobindo Pharma (ARBN.BO, Buy)
• FY11E FY13E We expect We expect revenue and EPS CAGR of 15%/32% over FY11E-FY13E. business mix change to drive revenue growth as share of
higher quality formulations increases. Marquee partnerships with Pfizer and AstraZeneca to be key catalysts for growth, in our view
• Operating margin to expand by 360 bp over FY11E-FY13E driven by supply agreements and higher utilization. Balance sheet concerns also
coming to a close with the potential redemption of FCCBs in FY12E
• Stock is trading at 9.6X on FY12E P/E, at a 35% discount to the Indian pharma sector, which we believe is unwarranted
Aurobindo: Steep discount to peers unwarranted
> Aurobindo’s valuation discount set to reduce as quality of revenues improves
> Stock’s historical multiples volatile due to forex fluctuations
> 12-m target price is based on Director’s Cut
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Healthcare: Aurobindo Pharma (ARBN.BO, Buy)
• FY11E FY13E We expect We expect revenue and EPS CAGR of 15%/32% over FY11E-FY13E. business mix change to drive revenue growth as share of
higher quality formulations increases. Marquee partnerships with Pfizer and AstraZeneca to be key catalysts for growth, in our view
• Operating margin to expand by 360 bp over FY11E-FY13E driven by supply agreements and higher utilization. Balance sheet concerns also
coming to a close with the potential redemption of FCCBs in FY12E
• Stock is trading at 9.6X on FY12E P/E, at a 35% discount to the Indian pharma sector, which we believe is unwarranted
Aurobindo: Steep discount to peers unwarranted
> Aurobindo’s valuation discount set to reduce as quality of revenues improves
> Stock’s historical multiples volatile due to forex fluctuations
> 12-m target price is based on Director’s Cut
No comments:
Post a Comment